1. Efficacy and safety of mesenchymal stem cell therapy for ovarian ageing in a mouse model.
- Author
-
Pei, Wendi, Fu, Lin, Guo, Wenhuan, Wang, Yibo, Fan, Yong, Yang, Rui, Li, Rong, Qiao, Jie, and Yu, Yang
- Subjects
MESENCHYMAL stem cells ,STEM cell treatment ,LABORATORY mice ,RNA sequencing ,ANIMAL disease models ,OVARIAN follicle - Abstract
Background: Ovarian ageing is one of the major issues that impacts female fertility. Mesenchymal stem cell (MSC)-based therapy has made impressive progress in recent years. However, the efficacy and safety of MSCs, as nonautologous components, remain to be further verified. Methods: Two common sources of MSCs, umbilical cord-derived MSCs (UC-MSCs) and adipose tissue-derived MSCs (AD-MSCs), were orthotopically transplanted into a mouse model of ovarian ageing to evaluate their therapeutic effects. The safety of the treatment was further evaluated, and RNA sequencing was performed to explore the underlying mechanisms involved. Results: After orthotopic transplantation of MSCs into the ovary, the oestrous cycle, ovarian weight, number and proportion of primary follicles, granulosa cell proliferation, and angiogenesis were improved. The effects of AD-MSCs were superior to those of UC-MSCs in several indices, such as post-transplant granulosa cell proliferation, ovarian weight and angiogenesis. Moreover, the tumorigenesis, acute toxicity, immunogenicity and biodistribution of MSCs were evaluated, and both AD-MSCs and UC-MSCs were found to possess high safety profiles. Through RNA sequencing analysis, enhancement of the MAPK cascade was observed, and long-term effects were mainly linked to the activation of immune function. Conclusions: Orthotopic transplantation of MSCs displays significant efficacy and high safety for the treatment of ovarian ageing in mice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF